Barchart.com
[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! Screen on your Watchlists and Portfolios with Barchart Plus. FREE 30 Day Trial
Menu
Stocks | Futures | Watchlist | News | More
 
or
Watchlist | Portfolio | Dashboard
Site News
Contact
Market:
Faster, Cleaner, Better.
Menu

Incyte Corp (INCY)

Incyte Corp (INCY)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Notes
Alerts
Watch
Help
Go To:
Incyte Announces More Than 20 Abstracts Accepted for Presentation at the European Hematology Association (EHA) 2026 Congress Business Wire - Tue May 12, 8:30AM CDT

Data from pivotal Phase 3 frontMIND trial evaluating tafasitamab (Monjuvi ® /Minjuvi ® ) in first-line diffuse large b-cell lymphoma (DLBCL) selected for prestigious...

INCY : 98.82 (-0.31%)
Incyte Announces 24-Week Long-Term Data from Phase 3 TRuE-AD4 Trial of Opzelura® (ruxolitinib) Cream in Adults with Moderate Atopic Dermatitis Business Wire - Thu May 7, 7:50AM CDT

First presentation of Week 24 results from TRuE-AD4 study in adults with moderate atopic dermatitis (AD) who had an inadequate response, intolerance or contraindication to topical corticosteroids (TCSs)...

INCY : 98.82 (-0.31%)
INCY
2 Cash-Heavy Stocks with Solid Fundamentals and 1 We Ignore StockStory - Wed May 6, 11:34PM CDT

2 Cash-Heavy Stocks with Solid Fundamentals and 1 We Ignore

INSP : 41.92 (-4.86%)
INCY : 98.82 (-0.31%)
RJF : 153.96 (+0.31%)
Incyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Business Wire - Wed May 6, 3:30PM CDT

Incyte Corporation (Nasdaq:INCY) announced today that it granted equity inducement awards to Suketu (Suky) Upadhyay, the Company’s new Executive Vice President and Chief Financial Officer, pursuant to...

INCY : 98.82 (-0.31%)
INCY
Incyte’s Q1 Earnings Call: Our Top 5 Analyst Questions StockStory - Tue May 5, 12:40AM CDT

Incyte’s Q1 Earnings Call: Our Top 5 Analyst Questions

INCY : 98.82 (-0.31%)
Incyte Announces FDA Approval of Jakafi XR™ (ruxolitinib) Extended-Release Tablets for the Treatment of Myelofibrosis, Polycythemia Vera and Graft-Versus-Host Disease Business Wire - Fri May 1, 4:28PM CDT

Jakafi XR is a once-daily, film-coated, extended-release formulation of Jakafi ® (ruxolitinib) ...

INCY : 98.82 (-0.31%)
Incyte to Present at Upcoming Investor Conferences Business Wire - Wed Apr 29, 7:00AM CDT

Incyte (Nasdaq:INCY) announced today that it will present at the following investor conferences during the month of May: BofA Securities 2026 Health Care Conference on Wednesday,...

INCY : 98.82 (-0.31%)
INCY
INCY Q1 Deep Dive: Pipeline Advances Offset Cautious Full-Year Guidance StockStory - Wed Apr 29, 12:32AM CDT

INCY Q1 Deep Dive: Pipeline Advances Offset Cautious Full-Year Guidance

INCY : 98.82 (-0.31%)
INCY
Incyte (NASDAQ:INCY) Exceeds Q1 CY2026 Expectations StockStory - Tue Apr 28, 6:18AM CDT

Incyte (NASDAQ:INCY) Exceeds Q1 CY2026 Expectations

INCY : 98.82 (-0.31%)
Incyte: Q1 Earnings Snapshot AP - Tue Apr 28, 6:11AM CDT

Incyte: Q1 Earnings Snapshot

INCY : 98.82 (-0.31%)

Barchart Exclusives

Yield Is No Longer King: What These 5 Dividend ETFs Are Telling Investors Barchart - Wed May 13, 6:30PM CDT
Dividend investing has changed, and yield is misunderstood or misused by many investors. Let's take a closer look at 5 ETFS and discuss what dividend investors should know. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.